| __timestamp | Amphastar Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 5114000 |
| Thursday, January 1, 2015 | 46974000 | 13403000 |
| Friday, January 1, 2016 | 47298000 | 31056000 |
| Sunday, January 1, 2017 | 50918000 | 35845000 |
| Monday, January 1, 2018 | 58044000 | 48294000 |
| Tuesday, January 1, 2019 | 63109000 | 63488000 |
| Wednesday, January 1, 2020 | 65157000 | 88208000 |
| Friday, January 1, 2021 | 68920000 | 102802000 |
| Saturday, January 1, 2022 | 66592000 | 102464000 |
| Sunday, January 1, 2023 | 80393000 | 76162000 |
| Monday, January 1, 2024 | 72977000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology and pharmaceuticals, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc., from 2014 to 2023.
Amphastar Pharmaceuticals, Inc. has shown a steady increase in SG&A expenses, peaking in 2023 with an 80% rise from 2014. Meanwhile, CRISPR Therapeutics AG experienced a dramatic surge, with expenses skyrocketing by over 1,300% during the same period. This reflects CRISPR's aggressive expansion and investment in cutting-edge gene-editing technologies.
The data highlights a pivotal trend: while Amphastar maintains a consistent growth trajectory, CRISPR's rapid escalation underscores its commitment to innovation. As the biotech sector continues to expand, understanding these financial dynamics is crucial for investors and industry stakeholders.
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.